Over the past fifteen months, InterVenn has made considerable progress on the development of several assays across oncology and immunology. Upon review of the latest information related to InterVenn’s Advanced Adenoma (AA) and Colorectal Cancer (CRC) efforts, the company has decided to reprioritize investment to accelerate the development and commercialization of the AA and CRC franchise. It is expected that enrollment in the 3,000-patient prospective Noninvasive Identification of CRC and Adenomas in Early Stages (NICE, NCT05445570) study will be completed by year end, with final results available in the first half of 2023.
“Erwin Estigarribia is a talented leader who has been instrumental in InterVenn’s success over the last few years. His expanded leadership role will accelerate value creation of the AA and CRC franchise at InterVenn,” said Aldo Carrascoso, Co-Founder and CEO of InterVenn Biosciences. “Further validation and commercialization of InterVenn’s glycoproteomic-based platform will help transform the detection of early-stage disease and change the way the medical community approaches the detection and understanding of disease.”
“I am honored to step into this new role at InterVenn as we will continue the development of solutions that have the potential to impact how clinicians identify and understand disease. InterVenn is successfully executing a strategy that will reduce the rate of deaths from cancer and other life-threatening conditions by detecting disease at earlier stages than is conventionally possible today,” said Estigarribia. “As we transition to being a commercial company, I am excited to lead the efforts to engage with payers and oversee the product strategy of our AA and CRC platform for early detection of cancer and adenomas.”
Estigarribia was recently named one of the Top 25 Health Tech COOs, as reported by Becker’s Hospital Review. Before joining InterVenn, Estigarribia held executive-level positions at global life sciences companies, including Chiron, Novartis, Geron, Nugen, CardioDX, and Applied Proteomics. He graduated with a bachelor’s degree in chemical and bioprocessing engineering (with honors) from Swinburne University of Technology, Melbourne Australia.
NICE Study: Non-Invasive Identification of Colorectal Cancer and Adenomas in Early Stages
In May 2022, InterVenn started enrolling 3,000 patients in a prospective study to train and validate a blood-based, glycoproteomic test for the early detection of AA and CRC. The study, known as Noninvasive Identification of Colorectal Cancer and Adenomas in Early Stages (the NICE Study), is intended to validate InterVenn’s platform to detect early CRC and precancerous adenomas by collecting blood samples and associated relevant clinical information from average-risk participants undergoing routine screening colonoscopy as well as participants undergoing colonoscopy for surveillance or diagnostic indication. Following completion of the NICE study, InterVenn intends to introduce a product that could significantly improve diagnosis and treatment of cancer.
Early detection of CRC remains a huge unmet need, despite years of effort to find solutions. Colorectal cancer is the second leading cause of cancer-related death in the US, but about a third of adults aged 50-75 are not up to date with CRC screening, and more than 44 million people who are eligible for CRC screening have not yet been screened, according to the Centers for Disease Control and Prevention (CDC).